Original ArticleNon–Small Cell Lung CancerConsolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs
Non–Small Cell Lung Cancer
Under an Elsevier user license
open archive
Keywords
Oligometastases
Consolidation
Local ablative therapy
EGFR–tyrosine kinase inhibitor
NSCLC
Cited by (0)
Drs. Q. Xu, F. Zhou, and Liu contributed equally to this paper.
Disclosure: The authors declare no conflict of interest.
© 2018 International Association for the Study of Lung Cancer. Published by Elsevier Inc.